- Home
- GRNT vs MLYS Comparison
GRNT vs MLYS Comparison
Compare GRNT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- MLYS
- Stock Information
- Founded
- GRNT 2013
- MLYS 2019
- Country
- GRNT United States
- MLYS United States
- Employees
- GRNT N/A
- MLYS N/A
- Industry
- GRNT Blank Checks
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- GRNT Finance
- MLYS Health Care
- Exchange
- GRNT Nasdaq
- MLYS Nasdaq
- Market Cap
- GRNT 793.2M
- MLYS 890.6M
- IPO Year
- GRNT N/A
- MLYS 2023
- Fundamental
- Price
- GRNT $5.41
- MLYS $36.31
- Analyst Decision
- GRNT Buy
- MLYS Strong Buy
- Analyst Count
- GRNT 2
- MLYS 6
- Target Price
- GRNT $7.50
- MLYS $42.60
- AVG Volume (30 Days)
- GRNT 565.0K
- MLYS 2.6M
- Earning Date
- GRNT 11-06-2025
- MLYS 11-10-2025
- Dividend Yield
- GRNT 8.16%
- MLYS N/A
- EPS Growth
- GRNT N/A
- MLYS N/A
- EPS
- GRNT 0.25
- MLYS N/A
- Revenue
- GRNT $409,332,000.00
- MLYS N/A
- Revenue This Year
- GRNT $34.49
- MLYS N/A
- Revenue Next Year
- GRNT $13.97
- MLYS N/A
- P/E Ratio
- GRNT $21.91
- MLYS N/A
- Revenue Growth
- GRNT 10.32
- MLYS N/A
- 52 Week Low
- GRNT $4.52
- MLYS $8.24
- 52 Week High
- GRNT $7.00
- MLYS $39.20
- Technical
- Relative Strength Index (RSI)
- GRNT 50.39
- MLYS 83.59
- Support Level
- GRNT $5.19
- MLYS $35.00
- Resistance Level
- GRNT $5.67
- MLYS $39.20
- Average True Range (ATR)
- GRNT 0.17
- MLYS 2.56
- MACD
- GRNT -0.01
- MLYS 1.67
- Stochastic Oscillator
- GRNT 37.50
- MLYS 88.85
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.